Want to see MXCT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
MXCT Q2 2026 EPS Results
Actual EPS-$0.08
Consensus EPS-$0.09
Beat/MissBeat by +<$0.01
One Year Ago EPS-$0.12
MXCT Q2 2026 Revenue Results
Actual Revenue$7.27M
Expected Revenue$6.51M
Beat/MissBeat by +$765.00K
YoY Revenue Growth-14.53%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
MXCT Upcoming Earnings
MaxCyte's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MXCT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed a company that has stabilized near-term revenue, materially reduced operating expenses, and strengthened its strategic positioning through a large enterprise partnership (Genentech), while maintaining a strong balance sheet. These positives were offset by notable year-over-year revenue declines, gross margin pressure due to product mix, and prior partner/program headwinds. Management reiterated guidance and expects a return to growth in H2 2026, with further upside tied to SPL royalties and instrument adoption.Company Guidance
Stabilized Q2 Results with Sequential Growth
Total revenue of $7.3M in Q2 2026 (core $6.5M, SPL program-related $0.8M). Management reported sequential revenue growth in Q2 vs Q1 driven by instrument placements across the portfolio, including ExPERT DTx.
Strategic Multiplatform Partnership with Genentech
Announced an enterprise-level, multiplatform technology license partnership with Genentech covering ExPERT GTx, electroporation and analytical capabilities across research, clinical development and cGMP manufacturing — positioned to expand addressable market and monetize earlier in customer lifecycles.
Improved Cost Discipline and Reduced Operating Loss
Total operating expenses decreased ~25% year-over-year to $15.8M (from $21.2M) reflecting restructuring and cost-efficiency actions; management expects limited meaningful expense growth from current levels while continuing strategic R&D investments.
Strong Balance Sheet and Share Repurchase
Ended Q2 with $141.9M in cash and investments, no debt. Board authorized $10M buyback; ~$5.5M repurchased to date. Expected year-end cash at least $130.5M (excluding further repurchases).
SPL Royalty Momentum Driven by CASGEVY
SPL program-related revenue rose to $0.8M in Q2 2026 vs $0.3M in Q2 2025 (~+167% YoY) driven largely by Vertex CASGEVY commercial traction. Vertex reported ~$76M CASGEVY revenue in Q2 (≈75% sequential growth vs Q1 and ~150% YoY), supporting future royalty potential.
Product & Service Adoption: ExPERT DTx and SeQure Progress
ExPERT DTx adoption building across discovery, process development and early clinical workflows; SeQure showed continued positive momentum with $0.5M in revenue (licenses + services) and management expects year-over-year growth for SeQure assay services and licenses in 2026.
Robust Partner Pipeline and Diversified Commercial Models
Company reports 30 total license partnerships (29 SPLs + Genentech enterprise deal). Management highlights 5 partner programs with potential to begin commercial launches in the next couple of years, and ability to monetize via both SPLs and enterprise platform agreements.
Reiterated 2026 Guidance
Reiterated 2026 revenue guidance of $30M–$32M (core $25M–$27M; SPL milestones & royalties $5M with $3M milestones already received in Q1 and $2M of expected royalties). Company expects low single-digit YoY revenue growth in H2 2026 and typical seasonality with Q4 > Q3.
MXCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed